Sanofi reports that it is in exclusive negotiations with CD&R, an investment firm, for the potential sale of a 50% controlling stake in its consumer healthcare business, Opella. 

CD&R has made a binding offer. The valuation of Opella is based on an enterprise value of EUR 16 billion ($17 billion). The sale price of Sanofi’s stake was not disclosed.. The proposed transaction is subject to finalization of definitive agreements, completion of the appropriate social processes, and subject to customary statutory approvals. The anticipated closing of the transaction would be in the second quarter of 2025 at the earliest. 

If the deal progresses, Sanofi would remain a significant shareholder in Opella, with Opella becoming a pure-play and stand-alone consumer healthcare company. Bpifrance (Banque Publique D’Investissement), a French public sector investment bank,  is expected to participate as a minority shareholder with an approximate 2% stake. 

Headquartered in France, Opella employs over 11,000 people, operates in 100 countries with 13 manufacturing sites and four science and innovation development centers. Its product portfolio includes over-the-counter products, such as Allegra, Doliprane, and Dulcolax.  

Source: Sanofi